Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BBO-11818 |
| Synonyms | |
| Therapy Description |
BBO-11818 is a selective pan-KRAS inhibitor with activity against KRAS variants including G12D and G12V, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4378). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BBO-11818 | BBO 11818|BBO11818 | KRAS G12D Inhibitor 25 KRAS Inhibitor 30 | BBO-11818 is a selective pan-KRAS inhibitor with activity against KRAS variants including G12D and G12V, potentially leading to decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4378). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06917079 | Phase I | BBO-11818 + Pembrolizumab BBO-11818 + Cisplatin + Pembrolizumab + Pemetrexed Disodium BBO-11818 + Carboplatin + Pembrolizumab + Pemetrexed Disodium BBO-11818 + Cetuximab BBO-11818 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Recruiting | USA | 0 |